Market Place
Sourcing Support
Minoryx knocked back by EMA but vows to seek rerun of review
26 Jan 2024 //
FIERCE BIOTECH
FDA grants clearance to Minoryx for Phase III trial of cALD therapy
01 Jun 2023 //
CLINICAL TRIALS ARENA
Minoryx and Neuraxpharm team to provide new therapy for rare CNS disorders
10 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
Minoryx‘s marketing authorization application for lead candidate leriglitazone
20 Sep 2022 //
PHARMIWEB
Minoryx pockets €51M to guide rare disease drug to market
31 May 2022 //
FIERCEBIOTECH
Minoryx presents topline results from Ph2/3 “ADVANCE” study significant
26 Jan 2021 //
PHARMIWEB
EIB provides Minoryx with up to €25 million to support development
30 Oct 2020 //
EIB
Minoryx & Sperogenix to develop and commercialize leriglitazone
22 Sep 2020 //
PRNASIA
Minoryx Therapeutics doses first patient with leriglitazone
12 May 2020 //
ALA
Minoryx receives approval from Spanish Regulatory ph2 Friedreich’s Ataxia
27 Feb 2019 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.